Resona Asset Management Co. Ltd. bought a new stake in STAAR Surgical (NASDAQ:STAA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,500,188 shares of the medical instruments supplier's stock, valued at approximately $36,411,000. Resona Asset Management Co. Ltd. owned about 3.04% of STAAR Surgical at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in STAA. Quarry LP acquired a new stake in shares of STAAR Surgical in the third quarter worth $50,000. KLP Kapitalforvaltning AS acquired a new stake in STAAR Surgical in the 4th quarter valued at $180,000. FMR LLC raised its position in STAAR Surgical by 79.3% in the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after purchasing an additional 3,136 shares during the period. Quantbot Technologies LP acquired a new position in shares of STAAR Surgical during the fourth quarter worth about $278,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in STAAR Surgical during the 4th quarter worth approximately $292,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.
STAAR Surgical Trading Down 2.8 %
STAA traded down $0.45 on Thursday, hitting $15.43. 441,267 shares of the company's stock were exchanged, compared to its average volume of 1,114,216. The stock has a fifty day moving average of $17.94 and a two-hundred day moving average of $24.22. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $51.81. The firm has a market cap of $760.84 million, a PE ratio of -37.63 and a beta of 0.75.
Wall Street Analyst Weigh In
STAA has been the subject of a number of analyst reports. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Mizuho lowered STAAR Surgical from an "outperform" rating to a "neutral" rating and cut their target price for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. William Blair downgraded shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Finally, Piper Sandler cut their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $25.29.
View Our Latest Report on STAAR Surgical
Insider Buying and Selling
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the business's stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of $21.50 per share, with a total value of $176,751.50. Following the completion of the acquisition, the insider now owns 10,878,007 shares in the company, valued at approximately $233,877,150.50. This represents a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have purchased 1,763,757 shares of company stock valued at $28,914,625. Insiders own 1.00% of the company's stock.
STAAR Surgical Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Stories
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
